APOA5 Q97X Mutation Identified Through Homozygosity Mapping Causes Severe Hypertriglyceridemia in a Chilean Consanguineous Family

Overview

Journal BMC Med Genet

Publisher Biomed Central

Specialty Genetics

Date 2012 Nov 16

PMID 23151256

Citations 5

Authors

Catalina Dussaillant

Valentina Serrano

Alberto Maiz

Susana Eyheramendy

Luis Rodrigo Cataldo

Matias Chavez

Susan V Smalley

Marcela Fuentes

Attilio Rigotti

Lorena Rubio

Carlos F Lagos

Jose Alfredo Martinez

Jose Luis Santos

Affiliations

Soon will be listed here.

Abstract

Background: Severe hypertriglyceridemia (HTG) has been linked to defects in LPL, APOC2, APOA5, LMF1 and GBIHBP1 genes. However, a number of severe HTG cases are probably caused by as yet unidentified mutations. Very high triglyceride plasma levels (>112 mmol/L at diagnosis) were found in two sisters of a Chilean consanguineous family, which is strongly suggestive of a recessive highly penetrant mutation. The aim of this study was to determine the genetic locus responsible for the severe HTG in this family.

Methods: We carried out a genome-wide linkage study with nearly 300,000 biallelic markers (Illumina Human CytoSNP-12 panel). Using the homozygosity mapping strategy, we searched for chromosome regions with excess of homozygous genotypes in the affected cases compared to non-affected relatives.

Results: A large homozygous segment was found in the long arm of chromosome 11, with more than 2,500 consecutive homozygous SNP shared by the proband with her affected sister, and containing the APOA5/A4/C3/A1 cluster. Direct sequencing of the APOA5 gene revealed a known homozygous nonsense Q97X mutation (p.Gln97Ter) found in both affected sisters but not in non-affected relatives nor in a sample of unrelated controls.

Conclusion: The Q97X mutation of the APOA5 gene in homozygous status is responsible for the severe hypertriglyceridemia in this family. We have shown that homozygosity mapping correctly pinpointed the genomic region containing the gene responsible for severe hypertriglyceridemia in this consanguineous Chilean family.

Citing Articles

Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.

Makhmudova U, Schulze P, Lorkowski S, Marz W, Geiling J, Weingartner O J Med Case Rep. 2024; 18(1):278.

PMID: 38872171 PMC: 11177521. DOI: 10.1186/s13256-024-04532-0.

Genetic variation in apolipoprotein A-V in hypertriglyceridemia.

Perera S, Hegele R Curr Opin Lipidol. 2023; 35(2):66-77.

PMID: 38117614 PMC: 10919278. DOI: 10.1097/MOL.0000000000000916.

A Clinical Case of a Homozygous Deletion in the Gene with Severe Hypertriglyceridemia.

Vasiluev P, Ivanova O, Semenova N, Strokova T, Taran N, Chubykina U Genes (Basel). 2022; 13(6).

PMID: 35741823 PMC: 9222921. DOI: 10.3390/genes13061062.

Periodontitis and diabetes interrelationships in rats: biochemical and histopathological variables.

Choubaya C, Chahine R, Zalloua P, Salameh Z J Diabetes Metab Disord. 2019; 18(1):163-172.

PMID: 31275887 PMC: 6581989. DOI: 10.1007/s40200-019-00403-4.

Functional variants of lipid level modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 genes in healthy Roma and Hungarian populations.

Sumegi K, Jaromi L, Magyari L, Kovesdi E, Duga B, Szalai R Pathol Oncol Res. 2015; 21(3):743-9.

PMID: 25573592 DOI: 10.1007/s12253-014-9884-5.

References

Forte T, Shu X, Ryan R . The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res. 2008; 50 Suppl:S150-5. PMC: 2674726. DOI: 10.1194/jlr.R800050-JLR200. View

Johansen C, Kathiresan S, Hegele R . Genetic determinants of plasma triglycerides. J Lipid Res. 2010; 52(2):189-206. PMC: 3023540. DOI: 10.1194/jlr.R009720. View

Pennacchio L, Olivier M, Hubacek J, Cohen J, Cox D, Fruchart J . An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294(5540):169-73. DOI: 10.1126/science.1064852. View

Shu X, Nelbach L, Weinstein M, Burgess B, Beckstead J, Young S . Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol. 2010; 30(12):2504-9. PMC: 2988087. DOI: 10.1161/ATVBAHA.110.210815. View

Wang J, Ban M, Kennedy B, Anand S, Yusuf S, Huff M . APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med. 2008; 5(11):730-7. DOI: 10.1038/ncpcardio1326. View

Pennacchio L, Olivier M, Hubacek J, Krauss R, Rubin E, Cohen J . Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002; 11(24):3031-8. DOI: 10.1093/hmg/11.24.3031. View

Beigneux A, Davies B, Gin P, Weinstein M, Farber E, Qiao X . Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007; 5(4):279-91. PMC: 1913910. DOI: 10.1016/j.cmet.2007.02.002. View

Priore Oliva C, Pisciotta L, Volti G, Sambataro M, Cantafora A, Bellocchio A . Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2004; 25(2):411-7. DOI: 10.1161/01.ATV.0000153087.36428.dd. View

Kathiresan S, Melander O, Guiducci C, Surti A, Burtt N, Rieder M . Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40(2):189-97. PMC: 2682493. DOI: 10.1038/ng.75. View

10.

Pennacchio L, Rubin E . Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol. 2003; 23(4):529-34. DOI: 10.1161/01.ATV.0000054194.78240.45. View

11.

Wang J, Cao H, Ban M, Kennedy B, Zhu S, Anand S . Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol. 2007; 27(11):2450-5. DOI: 10.1161/ATVBAHA.107.150680. View

12.

Dorfmeister B, Zeng W, Dichlberger A, Nilsson S, Schaap F, Hubacek J . Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol. 2008; 28(10):1866-71. DOI: 10.1161/ATVBAHA.108.172866. View

13.

Olivecrona G, Ehrenborg E, Semb H, Makoveichuk E, Lindberg A, Hayden M . Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res. 2009; 51(6):1535-45. PMC: 3035517. DOI: 10.1194/jlr.M002717. View

14.

Schaap F, Nierman M, Berbee J, Hattori H, Talmud P, Vaessen S . Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res. 2006; 47(10):2333-9. DOI: 10.1194/jlr.M500533-JLR200. View

15.

Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View

16.

Wang C, McConathy W, Kloer H, Alaupovic P . Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985; 75(2):384-90. PMC: 423500. DOI: 10.1172/JCI111711. View

17.

Hegele R, Pollex R . Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem. 2009; 326(1-2):35-43. DOI: 10.1007/s11010-008-0005-1. View

18.

Kluger M, Heeren J, Merkel M . Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis. 2008; 31(2):281-8. DOI: 10.1007/s10545-008-0863-4. View

19.

Calandra S, Priore Oliva C, Tarugi P, Bertolini S . APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol. 2006; 17(2):122-7. DOI: 10.1097/01.mol.0000217892.00618.54. View

20.

Collin G, Marshall J, Cardon L, Nishina P . Homozygosity mapping at Alström syndrome to chromosome 2p. Hum Mol Genet. 1997; 6(2):213-9. DOI: 10.1093/hmg/6.2.213. View